ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 25
- 试验地点
- 3
- 主要终点
- Disease-free survival
研究概览
简要总结
This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. The purpose is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients treated with apatinib versus placebo (phase IIb).
详细描述
This study has two parts. In the single arm phase IIa part, we will enroll 25 patients that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. All patients will receive apatinib. The purpose is to evaluate the disease free-survival (DFS) in these patients treated with apatinib. In the phase IIb part, patients will be randomized to apatinib or placebo in a ratio of 1:1. The estimated sample size is 78 in phase IIb. However, the final sample size in phase IIb will be determined based on results of the phase IIa part.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven nasopharyngeal carcinoma, with detectable pretreatment plasma EBV DNA
- •Have detectable plasma EBV DNA at the end of (+/- 1 week) curative radiotherapy or chemoradiotherapy (radiation dose > 66Gy), determined by the central lab
- •No clinical evidence of persistent loco-regional disease
- •No evidence of distant metastasis, based upon skeletal scintigraphy, chest X-ray examination, and liver ultrasound or other appropriate workup (e.g., CT, MRI or positron emission tomography (PET)/CT]) within 21 days prior to registration
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Anticipated survival >= 3 months
- •Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
- •Platelets > 80,000 cells/mm^3
- •Hemoglobin >= 8.0 g/dl (no transfusion within the last 14 days)
- •Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x institutional ULN
- •Creatinine clearance (CC) >= 50 ml/min estimated by Cockcroft-Gault formula
排除标准
- •Patients with stage III-IV disease (American Joint Committee On Cancer/Union for International Cancer Control 7th) and no contraindication to chemotherapy that didn't receive platinum based concurrent chemotherapy during radiation
- •Patients with tumor possibly invaded main vessels (e.g. encasement of the internal jugular artery/vein) at diagnosis; or tumor that, in the judgment of the investigator, likely to invade main vessels and cause life-threatening hemorrhage events during study
- •History of serious hemorrhage events or grade 3 or higher hemorrhage within 4 weeks prior to registration
- •Hypertension that couldn't be well controlled with single medication; unstable angina; angina diagnosed within the last 3 months; myocardial infarction within the last 6 months; cardiac arrhythmia that need long-term medication; grade 2 or higher cardiac dysfunction (NYHA)
- •Proteinuria
- •Coagulation dysfunction or predisposition to hemorrhage; on treatment of anticoagulation medication or vitamin K antagonist; low dose warfarin (1mg po qd) or aspirin (less than 100mg daily) were permitted as long as the international normalized ratio (INR) = < 1.5
- •Thrombosis within the last 1 year, except cured vein thrombosis related to vein indwelling catheter
- •Unhealed bone fracture or chronic unhealed wound
- •Illness that would interfere with oral medication, including dysphagia, chronic diarrhea, or ileus
- •Pregnant or lactating women
- •Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during and within 6 months after study
- •Current drug abuse or mentally disabled
- •History of congenital or acquired immune deficiency disease or organ transplantation
- •Major medical illness, which in the investigator's opinion would endanger the patients or interfere with the completion of therapy and follow up
研究组 & 干预措施
Apatinib
In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
干预措施: Apatinib (Drug)
Placebo
In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
干预措施: Placebo (Drug)
结局指标
主要结局
Disease-free survival
时间窗: 3 years
次要结局
- overall survival(5 years)
- Changes in quality of life (QOL) as assessed by EORTC QLQ-C30(2 years)
- Distance Metastasis Free Survival(3 years)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(2 years)
- Correlation of plasma EBV DNA load with the effect of apatinib on survival(3 years)
- Correlation of pretreatment serum VEGF level with the effect of apatinib on survival(3 years)
- Correlation of pretreatment serum VEGFR-2 level with the effect of apatinib on survival(3 years)
- Correlation of adverse event (hypertension) with the effect of apatinib on survival(3 years)
- Correlation of adverse event (hand-foot syndrome) with the effect of apatinib on survival(3 years)
- locoregional relapse free survival(3 years)
- Correlation of the change from baseline in serum VEGF level at 4 weeks with the effect of apatinib on survival(3 years)
- Correlation of the change from baseline in serum VEGFR-2 level at 4 weeks with the effect of apatinib on survival(3 years)
研究者
Jun Ma, MD
Prof.
Sun Yat-sen University